T M Zimmerman - JoVE Visualize

Showing results (1-10 of 12) with videos related to

Pageof 2

Sort By:

Cytokines, Cellular & Molecular Therapy|March 6, 1999

Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitorsT M Zimmerman, S F Williams

Cancer|October 22, 1998

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinomaT M Zimmerman, D L Grinblatt, R Malloy, et al.

Cytotherapy|September 15, 2009

The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis productK L Hollingsworth, T M Zimmerman, T Karrison, et al.

Bone Marrow Transplantation|March 1, 1995

Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvestsT M Zimmerman, W J Lee, J G Bender, et al.

Journal of Clinical Apheresis|June 4, 1999

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphomaT M Zimmerman, G C Michelson, R Mick, et al.

Bone Marrow Transplantation|June 1, 1995

Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapyT M Zimmerman, R Mick, S Myers, et al.

Bone Marrow Transplantation|May 22, 2001

A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancerG G Laport, G F Fleming, S Waggoner, et al.

Bone Marrow Transplantation|October 6, 2000

Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescueT M Zimmerman, W J Lee, J G Bender, et al.

Cytotherapy|June 4, 2002

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancerG G Laport, F H Valone, T M Zimmerman, et al.

Journal of Hematotherapy|December 1, 1995

Clinical use of selected and expanded peripheral blood CD34+ cells: a preliminary report of feasibility and safetyT M Zimmerman, S F Williams, J G Bender, et al.

Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:

Pageof 2

Cytokines, Cellular & Molecular Therapy|March 6, 1999

Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitorsT M Zimmerman, S F Williams

Cancer|October 22, 1998

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinomaT M Zimmerman, D L Grinblatt, R Malloy, et al.

Cytotherapy|September 15, 2009

The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis productK L Hollingsworth, T M Zimmerman, T Karrison, et al.

Bone Marrow Transplantation|March 1, 1995

Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvestsT M Zimmerman, W J Lee, J G Bender, et al.

Journal of Clinical Apheresis|June 4, 1999

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphomaT M Zimmerman, G C Michelson, R Mick, et al.

Bone Marrow Transplantation|June 1, 1995

Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapyT M Zimmerman, R Mick, S Myers, et al.

Bone Marrow Transplantation|May 22, 2001

A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancerG G Laport, G F Fleming, S Waggoner, et al.

Bone Marrow Transplantation|October 6, 2000

Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescueT M Zimmerman, W J Lee, J G Bender, et al.

Cytotherapy|June 4, 2002

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancerG G Laport, F H Valone, T M Zimmerman, et al.

Journal of Hematotherapy|December 1, 1995

Clinical use of selected and expanded peripheral blood CD34+ cells: a preliminary report of feasibility and safetyT M Zimmerman, S F Williams, J G Bender, et al.

Pageof 2